Gufic Biosciences · NSE: GUFICBIO · BSE: 509079
Q2 FY22 results · Jul–Sep 2021
Gufic Biosciences reported revenue from operations of ₹194.14 crore (up 61.3% from Q2 FY21) and net profit of ₹23.34 crore (up 42.9% from Q2 FY21) for Q2 FY22 (Jul–Sep 2021), on a standalone basis.
| Item | Q2 FY22 | Q2 FY21 | YoY | Q1 FY22 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 194.14 | 120.35 | +61.3% | 250.76 | −22.6% |
| Other income | 0.30 | 2.25 | −86.5% | 1.23 | −75.2% |
| Total income | 194.44 | 122.60 | +58.6% | 251.99 | −22.8% |
| Profit before tax | 30.39 | 22.01 | +38.1% | 41.54 | −26.8% |
| Net profit for the period | 23.34 | 16.33 | +42.9% | 31.21 | −25.2% |
| EPS, basic (₹) | 2.41 | 2.10 | not comparable | 3.22 | −25.2% |
| Net margin (%) | 12.0 | 13.6 | 12.4 |
Standalone
- Filed with BSE
- 04 Nov 2021, 12:13 IST
- Board meeting
- 03 Nov 2021
- Period
- 01 Jul 2021 to 30 Sep 2021
- Review status
- Unaudited
- Source
- XBRL filing on BSE